Lipid Nanoparticle Emulsion for Ticagrelor Solubility

Solution Overview

Problem

Current treatments for autism spectrum disorders (ASD) lack FDA-approved medications targeting core symptoms, with existing pharmaceuticals facing challenges in formulation, particularly for children and individuals with neurodevelopmental delays, due to low aqueous solubility of active ingredients and difficulties in delivering drugs across biological barriers.

Innovation Solution

A liquid lipid nanoparticle emulsion (LNE) formulation of ticagrelor, a water-insoluble drug, pre-dissolved in an oil/surfactant/cosurfactant mixture and emulsified in an aqueous solution, combined with water-soluble agents like zinc or magnesium salts, to enhance bioavailability and solubility, facilitating effective delivery across biological barriers.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If a water-insoluble drug like ticagrelor is used to treat ASD, then the drug can potentially target neuroinflammatory pathways, but the low aqueous solubility prevents effective delivery and reduces bioavailability

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSQuantity of substance

Solution Approach 1:

The patent introduces lipid nanoparticles as intermediary carriers that solubilize water-insoluble drugs like ticagrelor. The LNE formulation acts as a mediator between the hydrophobic drug and the aqueous biological environment, enabling effective delivery while maintaining drug stability and bioavailability

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent transforms the physical-chemical parameters of the drug delivery system by converting ticagrelor from an insoluble crystalline form into a solubilized state within lipid nanoparticle emulsions. This parameter change in solubility and dispersion enables the drug to be effectively administered via oral or intranasal routes

Inventive Principle:
Principle #35Parameter changes

2Ease of manufacture

If conventional pharmaceutical formulations are used, then manufacturing processes are straightforward, but the drugs cannot effectively cross biological barriers like the blood-brain barrier

Engineering Contradiction:
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The patent employs composite lipid nanoparticle formulations combining multiple components (lipids, surfactants, cosurfactants) in specific ratios to create a sophisticated delivery system. This composite structure enables both manufacturability and enhanced ability to cross biological barriers through optimized surface properties and particle characteristics

Inventive Principle:
Principle #40Composite materials

3Ease of operation

If FDA-approved atypical antipsychotics are used for ASD treatment, then irritability symptoms can be managed, but core social communication deficits and repetitive behaviors remain untreated

Engineering Contradiction:
Core Design Contradiction:
Ease of operationVSAdaptability or versatility

Solution Approach 1:

The patent positions the LNE-delivered ticagrelor as a multi-functional treatment that can simultaneously address multiple ASD core symptoms including social communication deficits, repetitive behaviors, and irritability, rather than treating only isolated symptoms like conventional antipsychotics

Inventive Principle:
Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The LNE formulation improves the bioavailability and solubility of ticagrelor, allowing for effective treatment of ASD symptoms and associated disorders, including neuroinflammatory conditions, by enabling targeted drug delivery and reducing behavioral problems.

Implementation Method 1

A liquid lipid nanoparticle emulsion (LNE) formulation of ticagrelor, a water-insoluble drug, pre-dissolved in an oil/surfactant/cosurfactant mixture and emulsified in an aqueous solution

Methodology Applied
Scientific EffectEmulsion: Emulsion

Data Source

PatentUS20240130968A1Methods and products for treating subjects with autism spectrum disorders
Publication Date: 2024.04.25
  • US20240130968A1 patent drawing
  • US20240130968A1 patent drawing
  • US20240130968A1 patent drawing

AI summary

Methods and products for treating a subject diagnosed with an autism spectrum disorder, an intellectual disability, an anxiety disorder, a mood disorder, a disorder of social interaction, irritability, aggression, self-injurious behavior, hyperactivity, inattention, or Fragile X syndrome or brain neuroinflammation by administering a water-insoluble ticagrelor or ticagrelor salt, pre-dissolved in oil/surfactant/cosurfactant mixture and emulsified in an aqueous solution, containing a second agent, which may include a magnesium ion containing-compound, a zinc ion containing-compound, a lysine or lysine salt, an arginine or arginine salt, lecithin, or a combination thereof.